Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Eli Lilly’s Virus Antibody Drug Starts Testing in Nursing Homes

Aug. 3, 2020, 10:45 AM

Eli Lilly & Co. will begin testing its Covid-19 antibody drug in nursing homes, a treatment with potential to protect vulnerable groups that vaccines may not cover.

The trial, dubbed BLAZE-2, will kick off on Monday at several nursing homes in the U.S. and marks the third phase of testing for the monoclonal antibody that Lilly co-developed with Canadian start-up AbCellera Biologics Inc. The study will enroll up to 2,400 participants across nursing homes who are either diagnosed with Covid-19 or at the risk of exposure.

They will be given one dose of the antibody -- isolated from one ...